期刊
JAMA NEUROLOGY
卷 76, 期 9, 页码 1099-1108出版社
AMER MEDICAL ASSOC
DOI: 10.1001/jamaneurol.2019.1456
关键词
-
资金
- NIA [R01-AG048927, P30-AG13846, RF1-AG057519, U01-AG032984, R01-AG033193, UF1-AG047133]
- Alzheimer's Disease Sequencing Project comprises 2 Alzheimer disease genetics consortia and 3 National Human Genome Research Institute
- Human Genome Sequencing Center at the Baylor College of Medicine [U54HG003273]
- Broad Institute Genome Center [U54HG003067]
- Washington University Genome Institute [U54HG003079]
- National Heart, Lung, and Blood Institute
- Intramural Research Programof the NIH National Library of Medicine
- Clinical Research Hospital Programfrom the French Ministry of Health [PHRC 2008/067]
- Centre National de Reference pour les Malades Alzheimer Jeunes
- Joint Programme-Neurodegenerative Disease Research PERADES (defining Genetic, Polygenic and Environmental Risk for Alzheimer's Disease, Using Multiple Powerful Cohorts, Focused Epigenetics and Stem CellMetabolomics)
- FP7 Aged BrainSysBio, France Genomique, Labex GENMED [ANR-10-LABX-0013]
- National Foundation for Alzheimer's Disease and Related Disorders
- Institut Pasteur de Lille
- Centre National de Genotypage, Inserm, Fondation pour la Recherche sur le Cerveau
- Lille Metropole Communaute Urbaine council
- French government's LABEX (Laboratory of Excellence Program Investment for the Future) program DISTALZ grant (Development of Innovative Strategies for a Transdisciplinary Approach to Alzheimer's Disease)
- Banque d'ADNet de cellules-Institut du Cerveau et de la Moelle epiniere (ICM-Inserm) [U1127-UPMC P6, UMRS 1127-CNRS, UMR7225]
- Fondation Leducq (Transatlantic Network of Excellence on the Pathogenesis of SVD of the Brain)
- EU Joint Programme-Neurodegenerative Disease Research project
- European Research Council
- European Union's Horizon 2020research and innovation programme [640643, 643417, 667375]
- [U01-AG049505]
- [U01-AG049506]
- [U01-AG049507]
- [U01-AG049508]
- [U01-AG052411]
- [U01-AG052410]
- [U01-AG052409]
- [U54-AG052427]
- [R01-AG036836]
- [P30-AG10161]
- [R01-AG15819]
- [R01-AG17917]
- [R01-AG36042]
- [U01-AG46512]
- [U24AG021886]
- [U24AG041689]
- [U01AG016976]
- European Research Council (ERC) [640643] Funding Source: European Research Council (ERC)
Key PointsQuestionAre there rare variants associated with Alzheimer disease among individuals who possess or lack the APOE epsilon 4 allele? FindingsThis case-control, whole-exome sequencing study of 10441 individuals identified a possibly novel association with a GPAA1 variant among those who lacked the APOE epsilon 4 allele, a finding that was replicated in independent data sets and supported by analyses of whole-genome and RNA sequencing data derived from human brain tissue. Novel associations were identified among individuals with the APOE epsilon 4 allele for variants in ISYNA1, OR8G5, IGHV3-7, and SLC24A3. MeaningThis study supports the apparent involvement of genes in Alzheimer disease whose effects are dependent on APOE genotype. ImportancePrevious genome-wide association studies of common variants identified associations for Alzheimer disease (AD) loci evident only among individuals with particular APOE alleles. ObjectiveTo identify APOE genotype-dependent associations with infrequent and rare variants using whole-exome sequencing. Design, Setting, and ParticipantsThe discovery stage included 10441 non-Hispanic white participants in the Alzheimer Disease Sequencing Project. Replication was sought in 2 independent, whole-exome sequencing data sets (1766 patients with AD, 2906 without AD [controls]) and a chip-based genotype imputation data set (8728 patients with AD, 9808 controls). Bioinformatics and functional analyses were conducted using clinical, cognitive, neuropathologic, whole-exome sequencing, and gene expression data obtained from a longitudinal cohort sample including 402 patients with AD and 647 controls. Data were analyzed between March 2017 and September 2018. Main Outcomes and MeasuresScore, Firth, and sequence kernel association tests were used to test the association of AD risk with individual variants and genes in subgroups of APOE epsilon 4 carriers and noncarriers. Results with P <= 1x10(-5) were further evaluated in the replication data sets and combined by meta-analysis. ResultsAmong 3145 patients with AD and 4213 controls lacking epsilon 4 (mean [SD] age, 83.4 [7.6] years; 4363 [59.3.%] women), novel genome-wide significant associations were obtained in the discovery sample with rs536940594 in AC099552 (odds ratio [OR], 88.0; 95% CI, 9.08-852.0; P=2.22x10(-7)) and rs138412600 in GPAA1 (OR, 1.78; 95% CI, 1.44-2.2; meta-P=7.81x10(-8)). GPAA1 was also associated with expression in the brain of GPAA1 (beta=-0.08; P=.03) and its repressive transcription factor, FOXG1 (beta =0.13; P=.003), and global cognition function (beta=-0.53; P=.009). Significant gene-wide associations (threshold P <= 6.35x10(-7)) were observed for OR8G5 (P=4.67x10(-7)), IGHV3-7 (P=9.75x10(-16)), and SLC24A3 (P=2.67x10(-12)) in 2377 patients with AD and 706 controls with epsilon 4 (mean [SD] age, 75.2 [9.6] years; 1668 [54.1%] women). Conclusions and RelevanceThe study identified multiple possible novel associations for AD with individual and aggregated rare variants in groups of individuals with and without APOE epsilon 4 alleles that reinforce known and suggest additional pathways leading to AD. This case-control study evaluates APOE associations with variants, using whole-exome sequencing, in participants with and without APOE epsilon 4 alleles.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据